ASH 2024 | Alliance A041501: the addition of inotuzumab to a pediatric-inspired chemo regimen for B-ALL
Daniel DeAngelo, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, briefly discusses the findings of the Alliance A041501 Phase III randomized trial (NCT03150693) investigating the addition of inotuzumab ozogamicin to a pediatric-inspired chemotherapy regimen in young adult patients with B-cell acute lymphoblastic leukemia (B-ALL). Dr DeAngelo notes the three-year survival rate was around 80%, but adding inotuzumab did not lead to a survival benefit compared to chemotherapy alone. However, reduced relapse rates are being observed in the inotuzumab arm with longer-term follow-up. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
The Alliance trial is a pediatric-inspired trial on the basis of the prior study by Wendy Stock, CALGB 10403. We made some minor permutations and after induction we randomized patients to receive inotuzumab versus just continue on with chemotherapy. The important thing about this study is that it really impacted the idea that pediatric-inspired trials have a role and the three-year survival was about 80%, which is far better than we’ve seen in the past...
The Alliance trial is a pediatric-inspired trial on the basis of the prior study by Wendy Stock, CALGB 10403. We made some minor permutations and after induction we randomized patients to receive inotuzumab versus just continue on with chemotherapy. The important thing about this study is that it really impacted the idea that pediatric-inspired trials have a role and the three-year survival was about 80%, which is far better than we’ve seen in the past. What was disappointing is we didn’t see an improvement in the inotuzumab arm versus control. However, the inotuzumab arm led to some early toxicity, but very few relapses. So it’s possible with dose optimization of the inotuzumab, we may get some mileage out of this and with longer follow-up, because we’re only seeing relapses now in the control arm and not the inotuzumab arm.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Amgen, Autolus, Blueprint, Gilead, Incyte, Jazz, Novartis, Pfizer, Servier, Takeda: Consultancy; Mt Sinai MPN Consortium: Other: Mt Sinai MPN Consortium; Daiichi-Sankyo, Fibrogen: Other: DSMB; AbbVie, Blueprint, GlycoMimetics, Novartis: Research Funding; Dana-Farber Cancer Institute: Current Employment.
